Evotec Announces the Successful Completion of the First Phase I Study with EVT 401

02-Jul-2009 - Germany

Evotec AG announced the successful completion of the first Phase I study with its P2X7 receptor antagonist EVT 401. EVT 401 is a small molecule drug candidate and a potentially novel approach to orally treat inflammatory conditions such as rheumatoid arthritis.

The study was a double-blind, placebo controlled study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of EVT 401. A total of 96 healthy male volunteers received single oral ascending doses of the compound as a suspension or capsule.

The compound was very safe and well tolerated and there were no serious adverse events or withdrawals. In addition, the pharmacodynamic assay used in this study demonstrated the ability of EVT 401 to block ATP-stimulated IL-1ß release in whole blood samples taken from subjects, thereby proving "on target" activity at well tolerated oral doses.

In Rheumatoid Arthritis, the first potential indication for EVT 401, there is a significant need for new oral therapies. Oral drugs can be used both as alternatives to and in combination with existing agents to increase the responder rates and potentially reduce or delay the need for expensive biological therapies.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances